Bone marrow transplantation for severe aplastic anemia: A randomized controlled study of conditioning regimens

Blood

Volumn 109, Issue 10, 2007, Pages 4582-4585

  Champlin, Richard E ^a   Perez, Waleska S ^b   Passweg, Jakob R ^c   Klein, John P ^b   Camitta, Bruce M ^b   Gluckman, Eliane ^d   Bredeson, Christopher N ^b   Eapen, Mary ^b   Horowitz, Mary M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 34248376573     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-10-052308     Document Type: Article

References (18)

1. Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504-514.
2. Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992;79:269-275.
3. Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73:606-613.
4. Storb R, Champlin RE. Bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant. 1991;8:69-72.
5. Deeg HJ, Self S, Storb R. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood. 1986;68:1363-1368.
6. Storb R, Prentice RL, Thomas ED. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anemia. Br J Haematol. 1983;55:573-585.
7. Hows J, Palmer S, Gordon-Smith EC. Cyclosporine and graft failure following bone marrow transplantation. Br J Haematol. 1985;60:611-617.
8. Champlin RE, Ho WG, Nimer SD, et al. Bone marrow transplantation for severe aplastic anemia: effect of a preparative regimen of cyclophosphamide-low- dose total-lymphoid irradiation and posttransplant cyclosporine- methotrexate therapy. Transplantation. 1990;49:720-724.
9. McGlave PB, Haake R, Kim T, Kersey J, Ramsay NKC. Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation. Blood. 1987;70:1325-1330.
10. Gluckman E, Socie G, Devergie A, Bourdeau-Esperou H, Traineau R, Cosset JM. Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: long-term follow-up. Blood. 1991;78:2451-2455.
11. Pierga J-Y, Socie G, Gluckman E, et al. Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation. Radiother Oncol. 1994;30:55-58.
12. Socie G, Henry-Amar M, Cosset JM, Devergie A, Girinsky T, Gluckman E. Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood. 1991;78:277-279.
13. Socie G, Kolb HJ, Ljungman P. Malignant diseases after allogeneic bone marrow transplantation: the case for assessment of risk factors. Br J Haematol. 1992;80:427-430.
14. Storb R, Weiden PL, Sullivan KM, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood. 1987;70:116-121.
15. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941-949.
16. Klein JP, Moeschberger JL. Survival Analysis: Techniques of Censored and Truncated Data. 2nd ed. New York, NY: Springer-Verlag; 2003.
17. Storb R, Blume KG, O'Donnell MR, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant. 2001;7:39-44.
18. Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol. 2005;130:747-751.